Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Liabilities and Shareholders Equity: 2017-2024

Historic Liabilities and Shareholders Equity for Protagonist Therapeutics (PTGX) over the last 8 years, with Dec 2024 value amounting to $744.7 million.

  • Protagonist Therapeutics' Liabilities and Shareholders Equity rose 16.20% to $701.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year increase of 31.77%. This contributed to the annual value of $744.7 million for FY2024, which is 108.05% up from last year.
  • As of FY2024, Protagonist Therapeutics' Liabilities and Shareholders Equity stood at $744.7 million, which was up 108.05% from $358.0 million recorded in FY2023.
  • In the past 5 years, Protagonist Therapeutics' Liabilities and Shareholders Equity ranged from a high of $744.7 million in FY2024 and a low of $247.9 million during FY2022.
  • In the last 3 years, Protagonist Therapeutics' Liabilities and Shareholders Equity had a median value of $358.0 million in 2023 and averaged $450.2 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first spiked by 109.45% in 2020, then declined by 28.69% in 2022.
  • Yearly analysis of 5 years shows Protagonist Therapeutics' Liabilities and Shareholders Equity stood at $324.5 million in 2020, then rose by 7.16% to $347.7 million in 2021, then dropped by 28.69% to $247.9 million in 2022, then skyrocketed by 44.38% to $358.0 million in 2023, then soared by 108.05% to $744.7 million in 2024.